Breast cancer passed down in families may be preventable by the medication Denosumab which is undergoing a five-year study in Austria. The Austrian Breast and Colorectal Cancer Study Group is leading the work as it examines the drug's effectiveness on 2950 patients with a hereditary disposition to this particular form of cancer according to an Austria Press Agency report. Speaking at a press conference on Thursday Professor Christian Singer from the Vienna General Hospital said the study will also examine the effects of Denosumab on healthy women who have a mutation in the BRCA1 gene reports Xinhua news agency. These
